Detection of Genetic Markers of Lung Cancer

Study summary

The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBiopsy of the major carinal area and Biopsy of abnormal & suspicious areas of the bronchial tree

Plus 4 other study approaches.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 24, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Pittsburgh

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: University of Pittsburgh
Interventions being studied: Procedure: Biopsy of the major carinal area; Procedure: Biopsy of abnormal & suspicious areas of the bronchial tree; Procedure: Evaluation of the tumor for DNA mutations; Procedure: Bronchoalveolar Lavage (BAL) for cytokine analysis; Procedure: Correlation of flow cytometric & RT PCR for TNM stage; Procedure: Analysis of lymph nodes

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Histologic confirmation of lung cancer, lung metastases from a primary site other than lung, mesothelioma or a radiographic lesion highly suspicious for malignancy
Written informed consent.
To be scheduled for a biopsy or surgical resection or have already had a biopsy and/or surgical removal of a lung mass

Reasons someone may not be able to joinExclusion criteria

None

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Hillman Cancer CenterPittsburgh, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 24, 2025. Always confirm current availability with the study team.

View original record ↗